JP5722524B2 - 補体活性を抑制することによる同種移植片の生存の延長 - Google Patents

補体活性を抑制することによる同種移植片の生存の延長 Download PDF

Info

Publication number
JP5722524B2
JP5722524B2 JP2008557383A JP2008557383A JP5722524B2 JP 5722524 B2 JP5722524 B2 JP 5722524B2 JP 2008557383 A JP2008557383 A JP 2008557383A JP 2008557383 A JP2008557383 A JP 2008557383A JP 5722524 B2 JP5722524 B2 JP 5722524B2
Authority
JP
Japan
Prior art keywords
antibody
composition
allograft
drug
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008557383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528369A5 (enExample
JP2009528369A (ja
Inventor
ラッセル ピー． ローター，
ラッセル ピー． ローター，
ハオ ワン，
ハオ ワン，
チェン チョン，
チェン チョン，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38475394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5722524(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド, アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2009528369A publication Critical patent/JP2009528369A/ja
Publication of JP2009528369A5 publication Critical patent/JP2009528369A5/ja
Application granted granted Critical
Publication of JP5722524B2 publication Critical patent/JP5722524B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2008557383A 2006-03-02 2007-03-02 補体活性を抑制することによる同種移植片の生存の延長 Expired - Fee Related JP5722524B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77885906P 2006-03-02 2006-03-02
US60/778,859 2006-03-02
PCT/US2007/005290 WO2007103134A2 (en) 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013105946A Division JP2013155202A (ja) 2006-03-02 2013-05-20 補体活性を抑制することによる同種移植片の生存の延長

Publications (3)

Publication Number Publication Date
JP2009528369A JP2009528369A (ja) 2009-08-06
JP2009528369A5 JP2009528369A5 (enExample) 2011-02-24
JP5722524B2 true JP5722524B2 (ja) 2015-05-20

Family

ID=38475394

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008557383A Expired - Fee Related JP5722524B2 (ja) 2006-03-02 2007-03-02 補体活性を抑制することによる同種移植片の生存の延長
JP2013105946A Withdrawn JP2013155202A (ja) 2006-03-02 2013-05-20 補体活性を抑制することによる同種移植片の生存の延長

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013105946A Withdrawn JP2013155202A (ja) 2006-03-02 2013-05-20 補体活性を抑制することによる同種移植片の生存の延長

Country Status (21)

Country Link
US (1) US20100135992A1 (enExample)
EP (2) EP2918269A1 (enExample)
JP (2) JP5722524B2 (enExample)
KR (2) KR101527225B1 (enExample)
CN (1) CN101437501B (enExample)
AU (1) AU2007224250B2 (enExample)
BR (1) BRPI0708424A2 (enExample)
CA (1) CA2644020C (enExample)
DK (1) DK1988882T3 (enExample)
ES (1) ES2530637T3 (enExample)
HR (1) HRP20150182T1 (enExample)
IL (1) IL193623A0 (enExample)
MX (1) MX2008011054A (enExample)
NZ (1) NZ570802A (enExample)
PL (1) PL1988882T3 (enExample)
PT (1) PT1988882E (enExample)
RS (1) RS53864B1 (enExample)
RU (1) RU2445975C2 (enExample)
SG (1) SG171578A1 (enExample)
SI (1) SI1988882T1 (enExample)
WO (1) WO2007103134A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
WO2008030505A2 (en) * 2006-09-05 2008-03-13 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
JP6223659B2 (ja) * 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
US20130028897A1 (en) * 2009-04-27 2013-01-31 Ali Naji Methods for reducing the level of alloantibodies in a subject
NZ597259A (en) * 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
JP5871798B2 (ja) * 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
CN101621801B (zh) * 2009-08-11 2012-11-28 华为终端有限公司 无线局域网的认证方法、系统及服务器、终端
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
AU2012256281B2 (en) * 2011-05-16 2017-06-15 Genzyme Corporation Induction of immune tolerance by using methotrexate
CN102585016B (zh) * 2012-03-06 2014-06-04 江苏健德生物药业有限公司 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
CN103232542B (zh) * 2013-02-01 2015-05-13 殷勇 一种双靶标嵌合蛋白
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
EP3033093A1 (en) * 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
ME03318B (me) * 2013-11-22 2019-10-20 Shire Viropharma Inc Postupci lečenja odbacivanja posredovanog antitelima pacijenata sa transplatiranim organom sa inhibitorom c1-esteraze
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
EP3368073B1 (en) * 2015-10-30 2024-05-15 Alexion Pharmaceuticals, Inc. A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy
CN108401431B (zh) * 2015-12-18 2022-01-25 中外制药株式会社 抗-c5抗体及使用方法
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
WO2017212391A1 (en) * 2016-06-07 2017-12-14 Novartis Ag An anti-c5 antibody dosing regimen
EP3463459A1 (en) * 2016-06-07 2019-04-10 Novartis AG Tesidolumab for use in the treatment of transplant rejection
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
ES2965486T3 (es) 2017-07-27 2024-04-15 Alexion Pharma Inc Formulaciones de anticuerpos anti-C5 de alta concentración
JP7518764B2 (ja) 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
EP3802593B1 (en) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
EP3802603A1 (en) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
JP7538723B2 (ja) 2018-06-28 2024-08-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体の産生方法
US12240893B2 (en) 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途
US20220213434A1 (en) 2019-05-10 2022-07-07 The Regents Of The University Of California Modified pluripotent cells
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
CN116870135A (zh) 2019-10-12 2023-10-13 睿诺医疗科技（上海）有限公司 肾毒素诱发的肾损伤的治疗和预防
EP4585223A3 (en) * 2020-01-15 2025-07-30 The Regents of the University of California Transplanted cell protection via inhibition of polymorphonuclear cells
AU2021256222A1 (en) 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症
CA3215371A1 (en) * 2021-04-13 2022-10-20 Shibeshih Mitiku BELACHEW Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome
CN114532982A (zh) * 2022-01-12 2022-05-27 高谋 评价干细胞系统移植调控补体活化作用的体系

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588579B2 (ja) 1988-04-21 1997-03-05 株式会社クラレ 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5573940A (en) 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US20010018051A1 (en) * 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
CA2097825A1 (en) 1990-12-06 1992-06-07 Henry C. Marsh, Jr. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
IL137614A0 (en) * 1998-02-04 2001-07-24 Gen Hospital Corp An inhibitor of a costimulatory pathway and hematopoietic stem cells for promoting graft acceptance
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
AU1521000A (en) 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US6538028B1 (en) * 2000-02-01 2003-03-25 Vanderbilt University Method for inhibiting complement activation
ATE449791T1 (de) 2000-10-10 2009-12-15 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
MXPA04001301A (es) 2001-08-17 2004-07-08 Tanox Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
US20030180301A1 (en) * 2002-01-22 2003-09-25 Shaf Keshavjee Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
US20040146503A1 (en) * 2002-08-28 2004-07-29 Tesi Raymond J. Methods and compositions for inducing stable immune tolerance
WO2005025509A2 (en) * 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
EP2338511A3 (en) * 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
MXPA06013463A (es) * 2004-05-17 2007-03-01 Combinatorx Inc Metodos y reactivos para el tratamiento de desordenes inmuno-inflamatorios.

Also Published As

Publication number Publication date
NZ570802A (en) 2012-03-30
AU2007224250B2 (en) 2012-05-03
US20100135992A1 (en) 2010-06-03
PL1988882T3 (pl) 2015-04-30
KR101527225B1 (ko) 2015-06-08
HRP20150182T1 (hr) 2015-06-05
KR101650264B1 (ko) 2016-08-22
MX2008011054A (es) 2009-03-03
PT1988882E (pt) 2015-02-17
SI1988882T1 (sl) 2015-07-31
CN101437501A (zh) 2009-05-20
ES2530637T3 (es) 2015-03-04
JP2013155202A (ja) 2013-08-15
WO2007103134A2 (en) 2007-09-13
CN101437501B (zh) 2012-09-05
BRPI0708424A2 (pt) 2011-05-31
EP1988882B1 (en) 2014-12-17
EP1988882A2 (en) 2008-11-12
WO2007103134A3 (en) 2008-09-12
KR20080098543A (ko) 2008-11-10
KR20140124023A (ko) 2014-10-23
HK1120444A1 (en) 2009-04-03
AU2007224250A1 (en) 2007-09-13
JP2009528369A (ja) 2009-08-06
SG171578A1 (en) 2011-06-29
CA2644020A1 (en) 2007-09-13
IL193623A0 (en) 2009-08-03
CA2644020C (en) 2016-05-10
RS53864B1 (sr) 2015-08-31
EP2918269A1 (en) 2015-09-16
RU2445975C2 (ru) 2012-03-27
DK1988882T3 (en) 2015-02-23
RU2008139118A (ru) 2010-04-10

Similar Documents

Publication Publication Date Title
DK1988882T3 (en) PROLONGED SURVIVAL OF A allograft by inhibiting complement activity
JP5590624B2 (ja) 補体活性を阻害することによる同種移植片の生存の延長
HK1120444B (en) Prolongation of survival of an allograft by inhibiting complement activity
AU2013200641A1 (en) Prolongation of survival of an allograft by inhibiting complement activity
HK1101962B (en) Prolongation of survival of an allograft by inhibiting complement activity
HK1157199A (en) Prolongation of survival of an allograft by inhibiting complement activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120629

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120730

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130520

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130529

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140516

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140603

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140630

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141229

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150326

R150 Certificate of patent or registration of utility model

Ref document number: 5722524

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees